Onkologie最新文献

{"title":"Clinical characteristics of 274 non-small cell lung cancer patients in China.","authors":"Yan Chen,&nbsp;Sheng Han,&nbsp;Min-Juan Zheng,&nbsp;Yan Xue,&nbsp;Wen-Chao Liu","doi":"10.1159/000350301","DOIUrl":"https://doi.org/10.1159/000350301","url":null,"abstract":"<p><strong>Background: </strong>The mortality from non-small cell lung cancer (NSCLC) in China is increasing, and studies about clinical characteristics of recent NSCLC are rare. The primary objective of this study was to explore clinical features in a large general hospital in Northwest China, and to determine risk factors for stage, pathology and survival, with a view to prevention and treatment of NSCLC as well as establishment and improvement of national medical insurance policies.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed the characteristics of NSCLC patients (n = 274), as well as risk factors for advanced stage and squamous cell carcinoma (SCC). Survival features in different groups were analyzed, as well as risk factors of survival. Follow-up was at least 3 years.</p><p><strong>Results: </strong>179 were male (65.3%); 136 had adenocarcinoma (49.6%) and 109 had SCC (39.8%); 186 (67.9%) had advanced-stage disease (IIIB-IV); 130 (47.4%) had smoking habits; 195 came from an urban area (71.2%); 69 had local urban resident basic medical insurance; 58% were younger than 60 years. Female, adenocarcinoma, rural patients were significantly younger than male, SCC, and urban patients. Pathology was the only independent risk factor for advanced stage. Age, sex, and smoking status were independent prognostic factors for SCC. The proportion of male SCC was higher than female SCC even without the influence of smoking. Without local urban resident basic medical insurance, higher stage and not having surgery, but not smoking status, were independent risk factors for lower median progression-free survival (PFS). Patients with adenocarcinoma and SCC in advanced stage accepting EGFR-TKI during treatment had a higher 1-year survival rate and longer overall survival (OS) compared with those never accepting EGFR-TKI. EGFR-TKI treatment and chemotherapy regimen numbers were independent risk factor for median OS in advanced adenocarcinoma and SCC patients.</p><p><strong>Conclusion: </strong>More prevention and screening should be carried out for the female and rural population. EGFR-TKI could benefit advanced NSCLCs. China's medical insurance policy has some adverse effect on NSCLC survival calling for further improvement.</p>","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 5","pages":"248-54"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000350301","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31443360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Developmental history: bendamustine yesterday, today, tomorrow].","authors":"Walter Werner,&nbsp;Michael Herold,&nbsp;Klaus Ruffert,&nbsp;Karlheinz Merkle,&nbsp;Axel Brakhage,&nbsp;Lorenzo Leoni,&nbsp;Bruce D Cheson","doi":"10.1159/000346104","DOIUrl":"https://doi.org/10.1159/000346104","url":null,"abstract":"a WERNER BioAgents, Jena, b 4. Medizinische Klinik, HELIOS Klinikum Erfurt, c Überörtliche Gemeinschaftspraxis für Hämatologie und Internistische Onkologie, Jena, d Oncology Consulting, Miesbach, e Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie (HKI), Jena, Deutschland f AGIRE Stiftung, Manno, Schweiz g Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 Suppl 1 ","pages":"2-10"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000346104","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31361574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Therapeutic strategies in multiple myeloma: the future role of bendamustine].","authors":"Hartmut Goldschmidt,&nbsp;Martin Kropff,&nbsp;Lars-Olof Mügge,&nbsp;Wolfram Pönisch","doi":"10.1159/000346107","DOIUrl":"https://doi.org/10.1159/000346107","url":null,"abstract":"ganfunktion ist die Hochdosis-Melphalantherapie (200 mg/m) mit nachfolgender autologer Stammzelltransplantation. Sie kann in Einzelfällen auch für ältere Patienten («medically fit patients») mit vertretbarem Morbiditätsund Mortalitätsrisiko erwogen werden. Im Hinblick auf eine mögliche Langzeitremission oder womöglich gar Kuration ist das Erreichen einer kompletten Remission (CR) ein wichtiges Therapieziel in der Primärtherapie des MM. Patienten, die nach hochdosierter Chemotherapie mit nachfolgender Stammzelltransplantation eine CR erreichen, bleiben signifikant länger progressfrei und haben eine längere Gesamtlebenserwartung [2]. Die Auswertung Heidelberger Daten zeigte ferner, dass das Langzeitüberleben auch mit der Dauer der CR korreliert. Patienten mit einer über mindestens 3 Jahre anhaltenden kompletten oder nahezu kompletten Remission hatten eine deutlich bessere Prognose als Patienten mit nur kurz anhaltendem Therapieerfolg. Mittlerweile stehen sensitivere Techniken (Durchflusszytometrie, PolymeraseKettenreaktion (PCR)) zur Verfügung, um das Therapieansprechen und insbesondere die Remissionstiefe zu beurteilen, woraus sich neue Responseparameter wie die stringente CR, die immunophänotypische CR und die molekulare CR ableiten lassen [3–6].","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 Suppl 1 ","pages":"19-26"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000346107","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31361576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RAS, BRAF, and TP53 gene mutations in Taiwanese colorectal cancer patients.","authors":"Ya-Sian Chang,&nbsp;Shun-Jen Chang,&nbsp;Kun-Tu Yeh,&nbsp;Tsai-Hsiu Lin,&nbsp;Jan-Gowth Chang","doi":"10.1159/000356814","DOIUrl":"https://doi.org/10.1159/000356814","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) plays an important role in cancer mortality and morbidity. This study examined colorectal tissues for RAS, BRAF, and TP53 gene mutations to assess their value as indicators of outcomes of CRC therapy.</p><p><strong>Material and methods: </strong>DNA was extracted from tissues taken from 165 patients with CRC. RAS gene mutations (exons 2 and 3) were detected by primer extension analysis. BRAF gene mutations (V600E) were detected by high resolution melting (HRM) analysis. TP53 gene mutations (exons 5-8) were detected by direct sequencing.</p><p><strong>Results: </strong>RAS, BRAF, and TP53 mutations occurred in 36.97% (61/165), 4.24% (7/165), and 37.58% (62/165), respectively. The KRAS mutation is a predictor for poor 5-year survival (p = 0.05), and the co-presence of KRAS and TP53 mutations correlates with lymph node involvement (p = 0.029), tumor stage (p = 0.029), and poor survival (p = 0.021). Multivariate analysis adjusted for tumor size, histologic grade, lymph node metastasis, sex, and age also indicated that KRAS mutations correlate significantly with overall survival (p = 0.036).</p><p><strong>Conclusion: </strong>The KRAS mutation is not present in about one-third of CRC patients, and therefore other gene mutations need to be investigated to better understand the molecular mechanisms of CRC and its treatment.</p>","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 12","pages":"719-24"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000356814","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31971226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of primary breast cancer at the surgical unit of the Charité 1984-1998.","authors":"Klaus-Jürgen Winzer,&nbsp;Anika Buchholz,&nbsp;Hans Guski,&nbsp;Hans-Dieter Frohberg,&nbsp;Felix Diekmann,&nbsp;Kurt Possinger,&nbsp;Willi Sauerbrei","doi":"10.1159/000356805","DOIUrl":"https://doi.org/10.1159/000356805","url":null,"abstract":"<p><strong>Background: </strong>We have analyzed the patient population of one clinic (Charité) over a period of 15 years. Besides the changes in the technical facilities and therapeutical guidelines during these years, this period also reflects the changes in the health system attributable to the reunification of East and West Germany. Until now only few analyses for breast cancer patients from the German speaking area have been reported.</p><p><strong>Patients and methods: </strong>All 2,062 patients undergoing surgical treatment for breast cancer between 1984 and 1998 were documented and followed up until 2007. The analysis included 1,560 patients with a primary breast cancer who fulfilled certain inclusion criteria. The treatment strategies applied to this population are presented in 3 time periods (1984-1990, 1991-1993, and 1994-1998). The effects of prognostic factors on overall survival were investigated using univariate analyses.</p><p><strong>Results: </strong>The percentage of pT1 tumors changed from 50.7% in the first period to 63.1% in the third period. The percentage of node-negative patients hardly changed with time (on average 61.6%). However, the percentage of patients with less than 10 assessed nodes decreased from 48.4% to 6.7% and 2.5% for the 3 periods, respectively. Therapeutic strategies changed drastically. Survival rate increased substantially, most likely due to improved therapeutic strategies, but also for other reasons not considered in the analysis.</p>","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 12","pages":"727-36"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000356805","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31971227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"miR-145 inhibits proliferation and invasion of esophageal squamous cell carcinoma in part by targeting c-Myc.","authors":"Feng Wang,&nbsp;Jin Xia,&nbsp;Nengchao Wang,&nbsp;Hong Zong","doi":"10.1159/000356978","DOIUrl":"https://doi.org/10.1159/000356978","url":null,"abstract":"<p><strong>Background: </strong>Accumulating evidence has shown that microRNAs (miRNAs) are aberrantly expressed in human esophageal cancer and crucial to tumorigenesis. Herein, we identified the role of miR-145 in esophageal squamous cell carcinoma (ESCC) development in vitro and in vivo.</p><p><strong>Material and methods: </strong>miR-145 expression was investigated in 40 ESCC samples as well as 5 ESCC cell lines by real-time polymerase chain reaction. Crystal violet and transwell assays were conducted to explore the effects of miR-145 on the proliferation and invasion of human ESCC cell lines, respectively. The impact of overexpression of miR-145 on putative target c-Myc was subsequently confirmed via Western blot.</p><p><strong>Results: </strong>miR-145 expression was frequently downregulated in ESCC specimens and cell lines compared with adjacent normal tissues (p < 0.05). Overexpression of miR-145 suppressed (p < 0.05) ESCC cell proliferation and invasion, as well as the growth of xenograft tumors in mice. Overexpression of miR-145 significantly decreased (p < 0.05) the protein level of c-Myc which has previously been identified as a direct target of miR-145.</p><p><strong>Conclusion: </strong>Our results demonstrate that overexpression of miR-145 inhibits tumor growth in part by targeting c-Myc. Our findings revealed that miR-145 may act as a tumor suppressor in ESCC, and its dysregulation may be involved in the initiation and development of human ESCC.</p>","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 12","pages":"754-8"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000356978","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31971230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of the number of removed lymph nodes at lobectomy in patients with positron emission tomography-computed tomography-negative N2 non-small cell lung cancer.","authors":"Yuan-Ming Tsai,&nbsp;Tsai-Wang Huang,&nbsp;Hsian-He Hsu,&nbsp;Cheng-Yi Cheng,&nbsp;Yu-Chieh Lin,&nbsp;Yeung-Leung Cheng,&nbsp;Hung Chang,&nbsp;Shih-Chun Lee","doi":"10.1159/000354631","DOIUrl":"https://doi.org/10.1159/000354631","url":null,"abstract":"<p><strong>Background: </strong>We assessed the relation between the extent of lymph node (LN) dissection and the prognosis for positron emission tomography-computed tomography (PET-CT)-negative patients with clinical early-stage non-small cell lung cancer (NSCLC), undergoing lobectomy and mediastinal LN dissection.</p><p><strong>Methods: </strong>277 patients with clinical stage I/II NSCLC who had undergone a preoperative PET-CT scan followed by lobectomy were analysed retrospectively. The prognostic value of age, maximum standardized uptake value (SUVmax) of the tumour, tumour size, carcinoembryonic antigen and number of dissected LNs was assessed to determine any association with overall survival and disease-free survival.</p><p><strong>Results: </strong>31 patients developed postoperative relapse, and multiple logistic regression revealed that the number of dissected LNs was an independent factor predicting relapse. Patients were categorized into groups according to the number of LNs dissected (group I, < 10; group II, ≥ 10). There were no statistical differences between 2 groups but group II patients had a lower relapse rate (6.3%, p = 0.003) and better disease-free survival (74.95 months, p = 0.045).</p><p><strong>Conclusions: </strong>Mediastinal LN dissection is still important for clinical early-stage NSCLC patients undergoing lobectomy even when the preoperative PET-CT is negative, and results in fewer relapses and improved disease-free survival.</p>","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 9","pages":"492-6"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000354631","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31746631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of the hsa-mir-499 (rs3746444) polymorphisms with gastric cancer risk in the Chinese population.","authors":"Xiao-Jin Wu,&nbsp;Yan-Yan Mi,&nbsp;Hui Yang,&nbsp;An-Kang Hu,&nbsp;Chen Li,&nbsp;Xiao-Dong Li,&nbsp;Qing-Guo Zhang","doi":"10.1159/000355518","DOIUrl":"https://doi.org/10.1159/000355518","url":null,"abstract":"<p><strong>Background: </strong>Single-nucleotide polymorphisms (SNPs) in microRNAs (miRNA) have been shown to be related with susceptibility to several human cancers. We evaluated the associations of rs3746444 in pre-miRNA hsa-mir-499 with the risk of gastric cancer (GC) in the Chinese population.</p><p><strong>Patients and methods: </strong>The rs3746444 (A>G) SNPs were genotyped in 201 GC and 213 non-cancer subjects in a case-control study by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis.</p><p><strong>Results: </strong>There was no significant overall difference in the genotype distributions of rs3746444 (A>G) SNPs between cases and controls. In the logistic regression analyses, no significantly increased risk of GC was found to be associated with variant genotypes.</p><p><strong>Conclusion: </strong>The rs3746444 (A>G) SNP is not associated with susceptibility to GC in the Chinese population.</p>","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 10","pages":"573-6"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000355518","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31792070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PPARγ against tumors by different signaling pathways.","authors":"Zhi Zhang,&nbsp;Ying Xu,&nbsp;Qinggang Xu,&nbsp;Yongzhong Hou","doi":"10.1159/000355328","DOIUrl":"https://doi.org/10.1159/000355328","url":null,"abstract":"<p><p>The peroxisome proliferator-activated receptor-γ (PPARγ) belongs to the nuclear hormone receptor superfamily, and is expressed in adipose tissue, skeletal muscle, spleen, heart, liver, placenta, lung, and ovary. PPARγ is a critical regulator of inflammation, adipocyte differentiation, glucose homeostasis, and tumorigenesis. The mechanism of PPARγ on tumor suppression is still unclear, but plenty of evidence shows that PPARγ provides new therapeutic targets for cancer. Here we give a review of how PPARγ and its ligands regulate tumorigenesis by different pathways.</p>","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 10","pages":"598-601"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000355328","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31792075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics, treatment and prognostic factors of patients with gynaecological malignancies treated in a palliative care unit at a university hospital.","authors":"Samantha Aeckerle,&nbsp;Marina Moor,&nbsp;Lothar R Pilz,&nbsp;Deniz Gencer,&nbsp;Ralf-Dieter Hofheinz,&nbsp;Wolf-Karsten Hofmann,&nbsp;Dieter Buchheidt","doi":"10.1159/000355642","DOIUrl":"https://doi.org/10.1159/000355642","url":null,"abstract":"<p><strong>Background: </strong>Limited clinical data have been published on patients suffering from advanced gynaecological malignancies treated in palliative care units, and little is known about prognostic factors.</p><p><strong>Methods: </strong>In a retrospective study, the data of 225 patients with breast, ovarian and cervical cancer treated in the palliative care unit of a university hospital between 1998 and 2009 were assembled. Clinical aspects and baseline symptoms, laboratory parameters, the clinical course, and outcome were evaluated.</p><p><strong>Results: </strong>225 patients (497 cases; cancer diagnoses: breast 79%, ovarian 13%, and cervix 8%) were included in the analysis. The main symptoms were weakness/fatigue (71%), pain (65%), anorexia/nausea (62%), and dyspnea (46%). Pain control was achieved in 85% of all cases, satisfying control of other symptoms in 80%. The median overall survival (OS) was 59 days. 53% of the patients died at the palliative care unit. In the Cox proportional hazards model, 8 parameters indicated an unfavourable outcome: anorexia/nausea, disordered mental status, elevated lactate dehydrogenase, γ-glutamyltransferase, leukocyte count, hypoalbuminaemia, anaemia and hypercalcaemia. Based on these parameters 3 risk groups were defined: low risk (0-2 factors), intermediate risk (3-5 factors), and high risk (6-8 factors). Median survival for high-risk group was 13 days, for intermediate group 61 days, and for low-risk patients 554 days (p < 0.0001).</p><p><strong>Conclusion: </strong>Weakness/fatigue, pain and anorexia were the main symptoms leading to the hospitalisation of patients with gynaecological malignancies. Symptom and pain control was accomplished in 80% of cases. 8 parameters were identified as indicating a poor outcome, and patients showing at least 6 or more of these factors had a very limited prognosis. Although studied retrospectively, these results may be helpful for individual treatment decisions in patients with advanced gynaecological malignancies. Prospective data and the introduction of documentation systems could help to gain more powerful knowledge about the quality of palliative care.</p>","PeriodicalId":19684,"journal":{"name":"Onkologie","volume":"36 11","pages":"642-8"},"PeriodicalIF":0.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000355642","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31833261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}